245 related articles for article (PubMed ID: 31645432)
1. The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis.
Wang X; Rusin A; Walkey CJ; Lin JJ; Johnson DL
J Biol Chem; 2019 Dec; 294(50):19255-19268. PubMed ID: 31645432
[TBL] [Abstract][Full Text] [Related]
2. Covalent small ubiquitin-like modifier (SUMO) modification of Maf1 protein controls RNA polymerase III-dependent transcription repression.
Rohira AD; Chen CY; Allen JR; Johnson DL
J Biol Chem; 2013 Jun; 288(26):19288-95. PubMed ID: 23673667
[TBL] [Abstract][Full Text] [Related]
3. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.
Shor B; Wu J; Shakey Q; Toral-Barza L; Shi C; Follettie M; Yu K
J Biol Chem; 2010 May; 285(20):15380-15392. PubMed ID: 20233713
[TBL] [Abstract][Full Text] [Related]
4. Maf1 and Repression of RNA Polymerase III-Mediated Transcription Drive Adipocyte Differentiation.
Chen CY; Lanz RB; Walkey CJ; Chang WH; Lu W; Johnson DL
Cell Rep; 2018 Aug; 24(7):1852-1864. PubMed ID: 30110641
[TBL] [Abstract][Full Text] [Related]
5. Maf1, a new player in the regulation of human RNA polymerase III transcription.
Reina JH; Azzouz TN; Hernandez N
PLoS One; 2006 Dec; 1(1):e134. PubMed ID: 17205138
[TBL] [Abstract][Full Text] [Related]
6. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
[TBL] [Abstract][Full Text] [Related]
7. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
9. Maf1 ameliorates cardiac hypertrophy by inhibiting RNA polymerase III through ERK1/2.
Sun Y; Chen C; Xue R; Wang Y; Dong B; Li J; Chen C; Jiang J; Fan W; Liang Z; Huang H; Fang R; Dai G; Yan Y; Yang T; Li X; Huang ZP; Dong Y; Liu C
Theranostics; 2019; 9(24):7268-7281. PubMed ID: 31695767
[No Abstract] [Full Text] [Related]
10. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
11. Two steps in Maf1-dependent repression of transcription by RNA polymerase III.
Desai N; Lee J; Upadhya R; Chu Y; Moir RD; Willis IM
J Biol Chem; 2005 Feb; 280(8):6455-62. PubMed ID: 15590667
[TBL] [Abstract][Full Text] [Related]
12. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
13. MAF1 represses CDKN1A through a Pol III-dependent mechanism.
Lee YL; Li YC; Su CH; Chiao CH; Lin IH; Hsu MT
Elife; 2015 Jun; 4():e06283. PubMed ID: 26067234
[TBL] [Abstract][Full Text] [Related]
14. EGF reverses multi-drug resistance via the p-ERK pathway in HepG2/ADM and SMMC7721/ADM hepatocellular carcinoma models.
Yan F; Bai LP; Gao H; Zhu CM; Lin L; Kang XP
Asian Pac J Cancer Prev; 2014; 15(6):2619-23. PubMed ID: 24761873
[TBL] [Abstract][Full Text] [Related]
15. Recovery of RNA polymerase III transcription from the glycerol-repressed state: revisiting the role of protein kinase CK2 in Maf1 phosphoregulation.
Moir RD; Lee J; Willis IM
J Biol Chem; 2012 Aug; 287(36):30833-41. PubMed ID: 22810236
[TBL] [Abstract][Full Text] [Related]
16. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma.
Zhang X; Lin C; Song J; Chen H; Chen X; Ren L; Zhou Z; Pan J; Yang Z; Bao W; Ke X; Yang J; Liang Y; Huang H; Tang D; Jiang L; Liu J
Cell Death Dis; 2019 Sep; 10(10):719. PubMed ID: 31558697
[TBL] [Abstract][Full Text] [Related]
17. Regulation of RNA polymerase III transcription by Maf1 in mammalian cells.
Goodfellow SJ; Graham EL; Kantidakis T; Marshall L; Coppins BA; Oficjalska-Pham D; Gérard M; Lefebvre O; White RJ
J Mol Biol; 2008 May; 378(3):481-91. PubMed ID: 18377933
[TBL] [Abstract][Full Text] [Related]
18. Facilitated recycling protects human RNA polymerase III from repression by Maf1 in vitro.
Cabart P; Lee J; Willis IM
J Biol Chem; 2008 Dec; 283(52):36108-17. PubMed ID: 18974046
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
20. MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass.
Phillips E; Ahmad N; Sun L; Iben J; Walkey CJ; Rusin A; Yuen T; Rosen CJ; Willis IM; Zaidi M; Johnson DL
Elife; 2022 May; 11():. PubMed ID: 35611941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
